Akebia Therapeutics, Inc.
HealthcareNASDAQ:AKBA · NASDAQ Global Market
+$0.03 today
Vol 5.23M · Avg 3.66M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-16.4%
avg -222.9%
ROIC
9.3%
avg -41.8%
ROA
-1.4%
avg -32.4%
Analysis
ROIC is currently the strongest return metric at 9.3% versus its period average of -41.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John Butler | Chief Executive Officer, President & Director | $1.46M | — | 62 | $3.37M | 1.26% |
Carolyn Rucci | Senior Vice President, Chief Legal Officer & Secretary | $933,304.00 | — | 45 | $641,304.00 | 0.24% |
Steven Keith Burke | Senior Vice President and Chief Research & Development Officer | $860,324.00 | — | 65 | $994,508.00 | 0.37% |
Erik John Ostrowski | Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer | $792,870.00 | — | 54 | $3.37M | 1.26% |
Nicholas Grund | Senior Vice President & Chief Commercial Officer | $728,914.00 | — | 56 | $592,994.00 | 0.22% |
Mercedes Carrasco | Senior Director of Investor & Corporate Communications | — | — | — | — | — |
Richard C. Malabre | Senior VP & Chief Accounting Officer | — | — | 65 | $312,772.00 | 0.12% |
Meredith Bowman | Senior Vice President & Chief People Officer | — | — | — | — | — |
Justin McCue | Senior VP & Chief Technology Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$86,587.50
Sells
16
$1.05M
Net Sentiment
$965,809.09
Net selling
Most Active
Butler John P.
5 transactions
1–10 of 17
Analysis
Insiders reported 1 buys worth $86,587.50 and 16 sells worth $1.05M over the last 12 months. That adds up to net selling of $965,809.09. Butler John P. was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +44.4% (14yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +44.4% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
$747.81M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages AKBA?
Akebia Therapeutics, Inc. (AKBA) lists 9 active executives. The top listed executive is Steven Keith Burke, Senior Vice President and Chief Research & Development Officer.
Are AKBA insiders buying or selling?
Recent insider activity shows net buying of $15.54M.
Explore More
Continue the stock analysis
Jump to another research area for this company.